ATM encodes a kinase that acts as a master controller of the cellular DNA damage response: it detects double-strand breaks and coordinates DNA repair, cell cycle arrest, or apoptosis through downstream targets including p53, BRCA1, and CHK2. Loss-of-function mutations in both copies of ATM cause ataxia telangiectasia, an autosomal recessive disorder characterized by neurological problems, immune deficiency, and cancer predisposition. ATM functions as a tumor suppressor: individuals with ataxia telangiectasia are prone to childhood lymphomas, leukemias, and breast cancer, while carriers of a single altered copy have increased risk of breast, pancreatic, prostate, and other cancers. Somatic ATM mutations also occur in lymphoid malignancies and solid tumors, and ATM-deficient cancers are often especially sensitive to DNA-damaging treatments.

ATM's loss of function causes ataxia telangiectasia and raises cancer risk in carriers, but this missense change (p.Tyr1442His) does not clearly fit that loss-of-function pattern. Its population frequency and computational scores fall just short of supporting either pathogenicity or benignity, leaving its effect on ATM's DNA-repair function unresolved. The VUS classification therefore means this variant's impact on cancer risk is currently unknown and requires further evidence.